Skip to content

Author

Alessandro Poggi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Long-term depletion of KIR3DL01+ NK cells by adeno-associated viral-vectored antibody delivery alters chronic SIV infection

Natural killer (NK) cells are key innate effectors during antiviral immune responses, with their activity regulated in part by interactions between polymorphic killer-cell immunoglobulin-like receptors (KIRs) on NK cells and their major histocompatibility complex class I (MHC I) ligands on target cells. In human immunodeficiency virus (HIV) infection, certain KIR and MHC I allelic combinations are associated with enhanced viral control and delayed disease progression. To interrogate the contribution of a common KIR+ NK cell subset to the immune response to simian immunodeficiency virus (SIV) infection of rhesus macaques, we depleted KIR3DL01+ cells using an adeno-associated virus (AAV) vector encoding a KIR3DL01-reactive monoclonal antibody. AAV delivery resulted in high and durable antibody expression with minimal anti-drug antibody responses, leading to sustained depletion of KIR3DL01+ NK cells from blood, lymph nodes, and gut-associated lymphoid tissue for more than nine months. Following intrarectal SIV challenge, there was no difference in peak viremia between the two groups. However, KIR3DL01-depleted animals exhibited a modest increase in chronic viremia, reaching statistical significance at multiple timepoints relative to KIR3DL01+ controls. Phenotypic analysis revealed ongoing NK cell maturation in peripheral blood and lymphoid tissue, accompanied by increased expression of activation and proliferation markers during acute and early chronic infection. An expansion of NKG2D+ NK cells was also observed in chronic SIV infection. These findings suggest that KIR3DL01+ NK cells contribute to the inhibition of SIV replication during chronic infection. Moreover, they demonstrate the feasibility of AAV-vectored antibody delivery for long-term, perhaps indefinite depletion of a lymphocyte subset in a nonhuman primate model.

Kjell Sandstrom, Grace N. Hagedorn, Sean C Robinson et al. · 0 citations
Review Open access Aug 2026

Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer

Endometrial cancer (EC) is characterized by significant molecular and immunological heterogeneity, which influences both disease progression and response to therapy. Although immune checkpoint blockade has improved the clinical management of selected EC subtypes, durable responses remain limited in many patients, particularly in tumors with poorly inflamed or mismatch repair-proficient/microsatellite-stable profiles. In this context, natural killer (NK) cells represent an important but still insufficiently explored component of anti-tumor immunity. NK cells can recognize transformed or stressed cells independently of antigen-specific priming, which may be relevant in EC tumors characterized by altered antigen presentation, immune exclusion, or limited T-cell responsiveness. Within the EC tumor microenvironment, NK-cell dysfunction is likely shaped by a complex interplay between defective recruitment, altered receptor–ligand interactions, suppressive cytokine networks, and tumor-driven immune remodeling. These mechanisms may reduce NK-cell cytotoxicity and favor immunoregulatory or tolerance-like phenotypes, some of which resemble programs involved in maternal–fetal immune tolerance. Here, we examine how EC may reshape NK-cell recruitment, phenotype, and function, and discuss how these alterations intersect with molecular tumor heterogeneity, immune escape, and emerging NK-directed therapeutic strategies. Particular attention is given to how NK-directed and NK-complementary approaches, including cytokine-based activation, NK-cell engagers, adoptive NK-cell transfer, chimeric antigen receptor natural killer cell (CAR-NK) platforms, and their integration with immune checkpoint blockade, may help address resistance in EC.

Alessandro Poggi, V. Bruno, Anna Di Spirito et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.